The European Centre for Disease Prevention and Control (ECDC) and the European Respiratory Society (ERS) have developed 21 patient-centred standards to guide clinicians and public health workers in their work to ensure optimal diagnosis, treatment and prevention of tuberculosis (TB) in Europe.

Will we reach the United Nations Sustainable Development Goal (SDG) for health by 2030 and the targets set for HIV/AIDS, hepatitis and tuberculosis?

The European Centre for Disease Prevention and Control (ECDC) has published comprehensive guidance on the management of latent tuberculosis infection (LTBI) targeted for European Union/European Economic Area (EU/EEA) countries.

None of the European Union (EU) Member States could demonstrate that they reach the EU target of 75% influenza vaccination coverage for vulnerable groups, according to a new report from the European Centre for Disease Prevention and Control (ECDC).

It should be. Despite being a curable disease, tuberculosis (TB) is still a challenging public health issue in the European Union and European Economic Area (EU/EEA), with over 55 000 TB infections reported annually and thousands of fatalities.

The first virus detections for the 2019/2020 season indicate co-circulation of influenza types A (71%) and B (29%) viruses in the WHO European Region. This is a mix which potentially could result in high mortality in elderly patients and a heavy burden on healthcare services, warns the European Centre for Disease Control and Prevention (ECDC) and World Health Organization (WHO) Regional Office for Europe in a joint assessment issued today.

Since the beginning of January, outbreaks of high pathogenic A(H5N8) and low pathogenic A(H5N1) avian influenza viruses have been reported in the central eastern part of Europe. To minimise risk, people that are exposed to potentially infected birds should avoid direct unprotected contact to birds or their droppings and take appropriate personal protection measures.

EU states are being urged to step up surveillance and biosecurity measures to guard against possible new outbreaks of avian influenza this year.

Based on a systematic literature review, ECDC assessed the efficacy, effectiveness and safety of newer and enhanced inactivated seasonal influenza (flu) vaccines among those 18 years or older. These assessed are MF59® adjuvanted, cell-based, high-dose, and recombinant haemagglutinin influenza vaccines.